首页> 中文期刊> 《海南医科大学学报(英文版)》 >Serum CA125, HE4 and ROMA index in elderly patients with ovarian cancer

Serum CA125, HE4 and ROMA index in elderly patients with ovarian cancer

         

摘要

cqvip:Objective:To study the value of serum tumor markers, carbohydrate antigen 125 (CA125), human epididymis secretory protein 4 (HE4) and ovarian cancer risk factor (ROMA) index in elderly patients with ovarian cancer, so as to provide a choice for clinical diagnosis.Methods:A total of 110 cases of ovarian cancer treated in our hospital in December 2017-December 2015 were selected as malignant group. In addition, 120 cases of benign ovarian tumors in the same period were selected as the benign group, and 92 healthy women who came to the hospital for health examination were selected as the control group. Serum HE4, CA125 levels and positive rates were detected by microparticle enzyme immunochemiluminescence assay, and ROMA index values were combined to assess the risk of ovarian cancer.Results:Malignant group serum CA125, HE4 level and ROMA index were significantly higher than those in the benign group and the control group, the level of CA125 in positive group was higher than control group, but the difference in level of HE4 and ROMA index between benign group and control group was not statistically significant. The positive rates of serum CA125, HE4 and ROMA index in malignant group were 76.4%, 92.7%, 96.4%, which were significantly higher than those in benign group (28.3%, 18.3%, 15%). The negative predictive value, positive predictive value, specificity and sensitivity of CA125 were all lower than those of HE4. The negative predictive value, positive predictive value, specificity and sensitivity of the combined ROMA index were higher than those of single diagnosis.Conclusions: Serum CA125, HE4 and ROMA index in elderly patients with ovarian cancer are significantly higher than those in elderly patients with benign ovarian tumors and healthy women. The combined diagnosis is the highest, with Gao Min's high sensitivity and specificity, which can be popularized in clinical practice.

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号